$ELTX
Elicio Therapeutics, Inc. Stock $eltx

$eltx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000160148522000022 Filed on March 30, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$25.94M	$28.31M	$460.0K
YoY Change	5539.35%	883.06%	-34.29%
Cost Of Revenue	$433.0K	$433.0K	$130.0K
YoY Change	233.08%	-63.61%	-56.67%
Gross Profit	$25.51M	$27.88M	$330.0K
YoY Change	7629.7%	1549.64%	-17.5%
Gross Profit Margin	98.33%	98.47%	71.74%
Selling, General & Admin	$4.206M	$18.49M	$3.120M
YoY Change	34.81%	2.77%	-24.64%
% of Gross Profit	16.49%	66.32%	945.45%
Research & Development	$6.668M	$48.70M	$11.07M
YoY Change	-39.77%	24.94%	5.93%
% of Gross Profit	26.14%	174.68%	3354.55%
Depreciation & Amortization	$32.00K	$100.0K	$10.00K
YoY Change	220.0%	0.0%	-50.0%
% of Gross Profit	0.13%	0.36%	3.03%
Operating Expenses	$10.87M	$48.70M	$14.18M
YoY Change	-23.31%	24.94%	-2.81%
Operating Profit	$14.63M	-$39.31M	-$13.85M
YoY Change	-205.66%	-28.89%	-2.4%
Interest Expense	-$16.00K	-$2.191M	-$5.400M
YoY Change	-99.7%	-73.44%	-7814.29%
% of Operating Profit	-0.11%
Other Income/Expense, Net	$272.0K	-$15.27M	-$9.570M
YoY Change	-102.84%	-38.53%	403.68%
Pretax Income	$14.89M	-$54.57M	-$28.88M
YoY Change	-151.56%	-31.87%	80.27%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	$14.89M	-$54.57M	-$28.88M
YoY Change	-151.56%	-31.87%	80.27%
Net Earnings / Revenue	57.4%	-192.76%	-6278.26%
Basic Earnings Per Share		-$1.93
Diluted Earnings Per Share	$496.9K	-$1.93	-$1.957M
COMMON SHARES
Basic Shares Outstanding	29.96M shares	28.24M shares
Diluted Shares Outstanding		28.24M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$88.76M	$88.76M	$34.60M
YoY Change	156.52%	156.45%
Cash & Equivalents	$88.76M	$88.76M	$34.61M
Short-Term Investments
Other Short-Term Assets	$498.0K	$1.685M	$360.0K
YoY Change	38.33%	-37.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$91.25M	$91.25M	$42.30M
YoY Change	115.73%	115.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$451.0K	$4.437M	$156.0K
YoY Change	189.1%	4.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$723.0K	$723.0K	$800.0K
YoY Change	-9.63%	-11.83%
Other Assets	$106.0K	$106.0K	$0.00
YoY Change
Total Long-Term Assets	$5.266M	$5.266M	$5.050M
YoY Change	4.28%	4.28%
TOTAL ASSETS
Total Short-Term Assets	$91.25M	$91.25M	$42.30M
Total Long-Term Assets	$5.266M	$5.266M	$5.050M
Total Assets	$96.51M	$96.51M	$47.35M
YoY Change	103.84%	103.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.710M	$4.710M	$5.578M
YoY Change	-15.56%	-15.59%
Accrued Expenses	$3.219M	$4.113M	$6.665M
YoY Change	-51.7%	-43.5%
Deferred Revenue	$2.301M		$3.942M
YoY Change	-41.63%
Short-Term Debt	$0.00	$0.00	$51.40M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$58.00K	$58.00K
YoY Change
Total Short-Term Liabilities	$11.30M	$11.30M	$107.4M
YoY Change	-89.49%	-89.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$235.0K	$635.0K
YoY Change	-100.0%	-63.28%
Other Long-Term Liabilities	$0.00	$3.475M	$29.70M
YoY Change	-100.0%	-88.3%
Total Long-Term Liabilities	$0.00	$3.710M	$635.0K
YoY Change	-100.0%	-87.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.30M	$11.30M	$107.4M
Total Long-Term Liabilities	$0.00	$3.710M	$635.0K
Total Liabilities	$15.01M	$15.01M	$137.8M
YoY Change	-89.11%	-89.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$215.1M		-$160.6M
YoY Change	33.99%
Common Stock	$300.0K		$156.0K
YoY Change	92.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00		$1.800M
YoY Change	-100.0%
Treasury Stock Shares	0.000 shares		316.1K shares
Shareholders Equity	$81.51M	$81.51M	-$90.45M
YoY Change
Total Liabilities & Shareholders Equity	$96.51M	$96.51M	$47.35M
YoY Change	103.84%	103.83%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$14.89M	-$54.57M	-$28.88M
YoY Change	-151.56%	-31.87%	80.27%
Depreciation, Depletion And Amortization	$32.00K	$100.0K	$10.00K
YoY Change	220.0%	0.0%	-50.0%
Cash From Operating Activities	-$14.36M	-$52.64M	$20.59M
YoY Change	-169.75%	130.0%	-563.74%
INVESTING ACTIVITIES
Capital Expenditures	-$36.00K	$382.0K	-$10.00K
YoY Change	260.0%	831.71%	-66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$36.00K	-$382.0K	-$10.00K
YoY Change	260.0%	831.71%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$107.5M
YoY Change		-20691.38%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	404.0K	$107.2M	200.0K
YoY Change	102.0%	104.49%	-95.91%
NET CHANGE
Cash From Operating Activities	-14.36M	-$52.64M	20.59M
Cash From Investing Activities	-36.00K	-$382.0K	-10.00K
Cash From Financing Activities	404.0K	$107.2M	200.0K
Net Change In Cash	-13.99M	$54.15M	20.78M
YoY Change	-167.34%	86.49%	4847.62%
FREE CASH FLOW
Cash From Operating Activities	-$14.36M	-$52.64M	$20.59M
Capital Expenditures	-$36.00K	$382.0K	-$10.00K
Free Cash Flow	-$14.33M	-$53.03M	$20.60M
YoY Change	-169.54%	131.26%	-567.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001601485
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-04321
CY2021	dei	Entity Registrant Name EntityRegistrantName	ANGION BIOMEDICA CORP
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-3430072
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	51 Charles Lindbergh Boulevard
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Uniondale
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11553
CY2021	dei	City Area Code CityAreaCode	415
CY2021	dei	Local Phone Number LocalPhoneNumber	655-4899
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01
CY2021	dei	Trading Symbol TradingSymbol	ANGN
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	365000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29958064	shares
CY2021	dei	Auditor Name AuditorName	Moss Adams LLP
CY2021	dei	Auditor Location AuditorLocation	Seattle, Washington
CY2021	dei	Auditor Firm AuditorFirmId	659
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88756000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34607000	USD
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	806000	USD
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1685000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7690000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	91247000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	42297000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	451000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3986000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4072000	USD
CY2021Q4	us-gaap	Investments Investments	723000	USD
CY2020Q4	us-gaap	Investments Investments	822000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	106000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2021Q4	us-gaap	Assets Assets	96513000	USD
CY2020Q4	us-gaap	Assets Assets	47347000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4710000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5578000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3219000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6665000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	894000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	611000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	58000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2301000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3942000	USD
CY2021Q4	angn	Warrant Liability Current WarrantLiabilityCurrent	114000	USD
CY2020Q4	angn	Warrant Liability Current WarrantLiabilityCurrent	10704000	USD
CY2021Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	0	USD
CY2020Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	51170000	USD
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Current SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent	0	USD
CY2020Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Current SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent	26001000	USD
CY2021Q4	angn	Financial Instruments Subject To Mandatory Redemption Carried At Fair Value Settlement Terms Share Value Amount Current FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent	0	USD
CY2020Q4	angn	Financial Instruments Subject To Mandatory Redemption Carried At Fair Value Settlement Terms Share Value Amount Current FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent	2518000	USD
CY2021Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	0	USD
CY2020Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	260000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11296000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	235000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	107449000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3475000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3847000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25865000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	635000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	15006000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	137796000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29959060	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15632809	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29959060	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15316721	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	300000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	156000	USD
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	316088	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1846000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	296445000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72136000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-103000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-333000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-215135000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160562000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	81507000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-90449000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96513000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47347000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27506000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	193000	USD
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	806000	USD
CY2020	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	2687000	USD
CY2021	us-gaap	Revenues Revenues	28312000	USD
CY2020	us-gaap	Revenues Revenues	2880000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	433000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	1190000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48698000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38977000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18488000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17986000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	67619000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	58153000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-39307000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-55273000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2919000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4910000	USD
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-7469000	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-11353000	USD
CY2021	angn	Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss	-3592000	USD
CY2020	angn	Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss	-264000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-245000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	668000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-58000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	905000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-99000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-71000	USD
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1847000	USD
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-8846000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15266000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24834000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-54573000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-80107000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	230000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-333000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54343000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-80440000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.43
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.43
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28244825	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28244825	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14762120	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14762120	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-18586000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3095000	USD
CY2020	angn	Stock Issued During Period Value Broker Warrants Exercised StockIssuedDuringPeriodValueBrokerWarrantsExercised	4000	USD
CY2020	angn	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	751000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	47000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	36000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4716000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-333000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-80107000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-90449000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-90449000	USD
CY2021	angn	Stock Issued During Period Value Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock	35754000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	12041000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	10000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	980000	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	18000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2458000	USD
CY2021	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12041000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	230000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-54573000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	81507000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-54573000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-80107000	USD
CY2021	us-gaap	Depreciation Depreciation	91000	USD
CY2020	us-gaap	Depreciation Depreciation	98000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	710000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	530000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1884000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7661000	USD
CY2021	angn	Non Cash Placement Agent Fee NonCashPlacementAgentFee	0	USD
CY2020	angn	Non Cash Placement Agent Fee NonCashPlacementAgentFee	1683000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	905000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4716000	USD
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-7469000	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-11353000	USD
CY2021	angn	Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss	-3592000	USD
CY2020	angn	Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss	-264000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2919000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4910000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	58000	USD
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-96000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-71000	USD
CY2021	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	3000	USD
CY2020	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	106000	USD
CY2021	angn	Increase Decrease In Grant Receivables IncreaseDecreaseInGrantReceivables	806000	USD
CY2020	angn	Increase Decrease In Grant Receivables IncreaseDecreaseInGrantReceivables	-440000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4016000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2020000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	106000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-866000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5607000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3709000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-713000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-560000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-27506000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	29807000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52643000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22888000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	382000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-382000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107487000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-522000	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	31223000	USD
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	20047000	USD
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2020	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	895000	USD
CY2021	angn	Proceeds From Financing Obligation ProceedsFromFinancingObligation	302000	USD
CY2020	angn	Proceeds From Financing Obligation ProceedsFromFinancingObligation	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	18000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		USD
CY2021	angn	Payments For Forward Stock Split Fractional Shares PaymentsForForwardStockSplitFractionalShares	10000	USD
CY2020	angn	Payments For Forward Stock Split Fractional Shares PaymentsForForwardStockSplitFractionalShares	0	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2458000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	36000	USD
CY2021	angn	Payments For Broker Warrant Exercises PaymentsForBrokerWarrantExercises	0	USD
CY2020	angn	Payments For Broker Warrant Exercises PaymentsForBrokerWarrantExercises	-4000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	861000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	751000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	980000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	47000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	107171000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52409000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-444000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54149000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29036000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34607000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5571000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88756000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34607000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021	angn	Stock Retired StockRetired	4210000	USD
CY2020	angn	Stock Retired StockRetired	0	USD
CY2021	angn	Issuance Of Broker Warrants IssuanceOfBrokerWarrants	0	USD
CY2020	angn	Issuance Of Broker Warrants IssuanceOfBrokerWarrants	1412000	USD
CY2021	angn	Accrued Interest Premium For Convertible Preferred Stock AccruedInterestPremiumForConvertiblePreferredStock	0	USD
CY2020	angn	Accrued Interest Premium For Convertible Preferred Stock AccruedInterestPremiumForConvertiblePreferredStock	295000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	624000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	88000	USD
CY2021	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2020	us-gaap	Notes Issued1 NotesIssued1	5000000	USD
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1443000	USD
CY2021	us-gaap	Depreciation Depreciation	100000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000	USD
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.55583
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	16.00
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	16.00
CY2021Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88800000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-215100000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	operatingSegment
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, change in fair value of warrant liabilities prior to IPO, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company's cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash equivalents in securities and money market funds with original maturities less than three months.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
CY2021Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2800000	USD
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2000000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	58000	USD
CY2021Q4	angn	Number Of Related Party Entities NumberOfRelatedPartyEntities	2	entity
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	800000	USD
CY2020	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	2700000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	64392000	USD
CY2021Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	13980000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	114000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.43
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2900000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4900000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	968000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	582000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	517000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	426000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	451000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156000	USD
CY2020	us-gaap	Depreciation Depreciation	100000	USD
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1978000	USD
CY2021Q4	angn	Prepaid Clinical Fees Current PrepaidClinicalFeesCurrent	168000	USD
CY2020Q4	angn	Prepaid Clinical Fees Current PrepaidClinicalFeesCurrent	0	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	275000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	0	USD
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	131000	USD
CY2020Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	5000000	USD
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	863000	USD
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	352000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	248000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	360000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1685000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7690000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1274000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3154000	USD
CY2021Q4	angn	Accrued Direct Research Costs Current AccruedDirectResearchCostsCurrent	1196000	USD
CY2020Q4	angn	Accrued Direct Research Costs Current AccruedDirectResearchCostsCurrent	1321000	USD
CY2021Q4	angn	Accrued Operating Liabilities Current AccruedOperatingLiabilitiesCurrent	749000	USD
CY2020Q4	angn	Accrued Operating Liabilities Current AccruedOperatingLiabilitiesCurrent	707000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1483000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3219000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6665000	USD
CY2021Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	11.57
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	USD
CY2021Q1	angn	Financial Instruments Subject To Mandatory Redemption Settlement Terms Share Value Amount Gross FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross	22308000	USD
CY2020Q4	angn	Financial Instruments Subject To Mandatory Redemption Settlement Terms Share Value Amount Gross FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross	22308000	USD
CY2021Q1	angn	Financial Instruments Subject To Mandatory Redemption Settlement Terms Share Value Amount Settlement Premium FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium	5577000	USD
CY2020Q4	angn	Financial Instruments Subject To Mandatory Redemption Settlement Terms Share Value Amount Settlement Premium FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium	5577000	USD
CY2021Q1	angn	Financial Instruments Subject To Mandatory Redemption Settlement Terms Share Value Amount Unamortized Discount And Fees FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees	9250000	USD
CY2020Q4	angn	Financial Instruments Subject To Mandatory Redemption Settlement Terms Share Value Amount Unamortized Discount And Fees FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees	1884000	USD
CY2021Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Current SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent	18635000	USD
CY2020Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Current SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent	26001000	USD
CY2020Q4	angn	Financial Instruments Subject To Mandatory Redemption Carried At Fair Value Settlement Terms Share Value Amount Issued In Convertible Note Exchange FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange	2254000	USD
CY2020Q4	angn	Financial Instruments Subject To Mandatory Redemption Carried At Fair Value Settlement Terms Share Value Amount Accumulated Change In Fair Value FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue	264000	USD
CY2020Q4	angn	Financial Instruments Subject To Mandatory Redemption Carried At Amortized Cost And Fair Value Settlement Terms Share Value Amount FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount	28519000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1800000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3479731	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.97
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15140000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1103721	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.44
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	189388	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.24
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	152939	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.40
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	10963	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.67
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4230162	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.92
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2499165	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.11
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.25
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.48
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6100000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12041000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4716000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1148123	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2739791	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2739791	shares
CY2020Q4	angn	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	7.00
CY2020	angn	Warrants And Rights Outstanding Weighted Average Remaining Contractual Term WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm	P4Y10M24D
CY2021	angn	Class Of Warrant Or Right Exercises In Period ClassOfWarrantOrRightExercisesInPeriod	1588756	shares
CY2021	angn	Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod	7.30
CY2021	angn	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	2912	shares
CY2021	angn	Class Of Warrant Or Right Weighted Average Exercise Price Expirations In Period ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod	8.03
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1148123	shares
CY2021Q4	angn	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	8.01
CY2021	angn	Warrants And Rights Outstanding Weighted Average Remaining Contractual Term WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm	P1Y2M12D
CY2021	angn	Class Of Warrant Or Right Exercises In Period Tendered ClassOfWarrantOrRightExercisesInPeriodTendered	613892	shares
CY2021Q1	angn	Class Of Warrant Or Right Conversion Price ClassOfWarrantOrRightConversionPrice	11.57
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1142000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1099000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	473000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	646000	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1615000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1745000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	44000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	91000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1659000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1836000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1179000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1081000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	624000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	88000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.110
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1289000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1305000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1209000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1104000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	516000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5423000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1054000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4369000	USD
CY2021Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P42M
CY2021	angn	Proceeds From Financing Obligation ProceedsFromFinancingObligation	300000	USD
CY2021	angn	Proceeds From Financing Obligation ProceedsFromFinancingObligation	302000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	7000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9000	USD
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.011
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	94000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	94000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	94000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	31000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	313000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	20000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	293000	USD
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	900000	USD
CY2021Q4	angn	Cares Act Employee Retention Credit CARESActEmployeeRetentionCredit	1500000	USD
CY2020Q4	angn	Cares Act Employee Retention Credit CARESActEmployeeRetentionCredit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-53547000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-78164000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1026000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1943000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54573000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-80107000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5460000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-12129000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4779000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-522000	USD
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	10239000	USD
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	12651000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.023
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.005
CY2021	angn	Effective Income Tax Rate Reconciliation Interest Percent EffectiveIncomeTaxRateReconciliationInterestPercent	-0.043
CY2020	angn	Effective Income Tax Rate Reconciliation Interest Percent EffectiveIncomeTaxRateReconciliationInterestPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.028
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.011
CY2021	angn	Effective Income Tax Rate Reconciliation Permanent Items Percent EffectiveIncomeTaxRateReconciliationPermanentItemsPercent	-0.073
CY2020	angn	Effective Income Tax Rate Reconciliation Permanent Items Percent EffectiveIncomeTaxRateReconciliationPermanentItemsPercent	-0.047
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	-0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.101
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.158
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	29211000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22686000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6752000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4718000	USD
CY2021Q4	angn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1224000	USD
CY2020Q4	angn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	956000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3070000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1323000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	536000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	658000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40793000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30344000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	37000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1046000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	874000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39710000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29470000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	118500000	USD
CY2021Q4	angn	Operating Loss Carryforward Subject To Expiration OperatingLossCarryforwardSubjectToExpiration	9600000	USD
CY2021Q4	angn	Operating Loss Carryforward Not Subject To Expiration OperatingLossCarryforwardNotSubjectToExpiration	108900000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3700000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2579000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1073000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	633000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	23000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1946000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3675000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2579000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2021Q4	angn	Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate	3675000	USD
CY2020Q4	angn	Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate	2579000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3675000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2579000	USD
CY2021	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	1
CY2021	angn	Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay One Hundred Percent Employer Match DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch	0.03
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-54573000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-80107000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28244825	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28244825	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14762120	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14762120	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.43
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.43
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5581300	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15816618	shares
CY2020Q4	angn	Shares Issuable Upon Conversion Of Convertible Notes Discount Rate SharesIssuableUponConversionOfConvertibleNotesDiscountRate	0.20
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD

Files In Submission

Name	View Source	Status
0001601485-22-000022-index-headers.html	Edgar Link	pending
0001601485-22-000022-index.html	Edgar Link	pending
0001601485-22-000022.txt	Edgar Link	pending
0001601485-22-000022-xbrl.zip	Edgar Link	pending
a200909flg-angionfirstamen.htm	Edgar Link	pending
a201210flg-angionsecondame.htm	Edgar Link	pending
a220311flg-angionthirdamen.htm	Edgar Link	pending
angion-descriptionofsecuri.htm	Edgar Link	pending
angion-executiveseparation.htm	Edgar Link	pending
angn-20211231.htm	Edgar Link	pending
angn-20211231.xsd	Edgar Link	pending
angn-20211231_cal.xml	Edgar Link	unprocessable
angn-20211231_def.xml	Edgar Link	unprocessable
angn-20211231_g1.jpg	Edgar Link	pending
angn-20211231_g2.jpg	Edgar Link	pending
angn-20211231_g3.jpg	Edgar Link	pending
angn-20211231_g4.jpg	Edgar Link	pending
angn-20211231_g5.jpg	Edgar Link	pending
angn-20211231_g6.jpg	Edgar Link	pending
angn-20211231_htm.xml	Edgar Link	completed
angn-20211231_lab.xml	Edgar Link	unprocessable
angn-20211231_pre.xml	Edgar Link	unprocessable
egoldberg-angionxformsepar.htm	Edgar Link	pending
ex231_angnx123121-10k.htm	Edgar Link	pending
ex311_angnx123121-revisedv.htm	Edgar Link	pending
ex312_angnx123121xrevisedc.htm	Edgar Link	pending
ex321angn-12312021x10k.htm	Edgar Link	pending
ex322_angnx123121x10k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
igseparationagreement-fina.htm	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_03.jpg	Edgar Link	pending
image_04.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_0c.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_12.jpg	Edgar Link	pending
image_13.jpg	Edgar Link	pending
image_2.jpg	Edgar Link	pending
licenseagreementangionvit2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
non-employeedirectorcompen.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
solara-angionxredactedclin.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTX
Elicio Therapeutics, Inc. Stock $eltx

2021 Q4 Form 10-K Financial Statement

#000160148522000022 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTX Elicio Therapeutics, Inc. Stock $eltx

2021 Q4 Form 10-K Financial Statement

#000160148522000022 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTX
Elicio Therapeutics, Inc. Stock $eltx